Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNITEPANC organoid-guided adjuvant therapy in resectable pancreatic cancer
2023-510490-34-00Phase 2Authorised
- Sponsor
- University Hospital Ulm
- Start
- Sep 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fluorouracil, irinotecan, oxaliplatin, folinic acid, gemcitabine and 2 more in pancreatic adenocarcinoma (PDAC) (2 cohorts), sponsored by University Hospital Ulm. Planned start Sep 2025; status: authorised.
02
Drugs
fluorouracilirinotecanoxaliplatinfolinic acidgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2023-510490-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510490-34-00.